Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Japan Inflation Expectations Rise as BOJ Rate Hike Timing Faces Uncertainty 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
U.S. Stock Futures Fall as Iran Tensions Escalate and Oil Prices Surge 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Morgan Stanley Warns Against Overestimating EV Demand Boost from Rising Oil Prices 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Oil Prices Surge as U.S.-Iran Tensions Escalate and Strait of Hormuz Closes 
Asian Stocks Rise as Tech Gains Offset US-Iran Tensions, Oil Prices Add Pressure 
The four types of dementia most people don’t know exist 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
